Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis
- PMID: 10468688
- DOI: 10.1046/j.1365-2036.1999.00560.x
Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis
Abstract
Background: Although 5-aminosalicylic acid (5-ASA) oral compounds are the standard maintenance treatment for ulcerative colitis in remission, some patients cannot use them because of side-effects. Clinical and experimental observations have suggested the potential role of probiotics in inflammatory bowel disease therapy.
Aim: To evaluate the effects on intestinal microflora and the clinical efficacy of a new probiotic preparation in patients with ulcerative colitis in remission.
Patients and methods: Twenty patients with ulcerative colitis, intolerant or allergic to 5-ASA, have been treated with a new probiotic preparation (VSL#3, CSL, Milan, Italy) containing 5x10(11) cells/g of 3 strains of bifidobacteria, 4 strains of lactobacilli and 1 strain of Streptococcus salivarius ssp. thermophilus. Two doses of 3 g were administered o.d. for 12 months. Faecal samples for stool culture were obtained from the patients at the beginning of the trial and after 10, 20, 40, 60, 75, 90 days, 12 months and at 15 days after the end of the treatment. The following bacterial groups have been evaluated in the faeces: total aerobic and anaerobic bacteria, enterococci, Streptococcus thermophilus, lactobacilli, bifidobacteria, Bacteroides, clostridia, coliforms. Patients were assessed clinically every two months, and assessed endoscopically at 6 and 12 months or in relapse.
Results: Faecal concentrations of Streptococcus salivarius ssp. thermophilus, lactobacilli and bifidobacteria increased significantly in all patients, compared to their basal level, from the 20th day of treatment (P<0.05) and remained stable throughout the study. Concentrations of Bacteroides, clostridia, coliforms, total aerobic and anaerobic bacteria did not change significantly during treatment (P = N.S.). Fifteen of 20 treated patients remained in remission during the study, one patient was lost to follow up, while the remaining relapsed. No significant side-effects have been reported.
Conclusions: These results show that this probiotic preparation is able to colonize the intestine, and suggest that it may be useful in maintaining the remission in ulcerative colitis patients intolerant or allergic to 5-ASA. Controlled trials are warranted to confirm these preliminary results.
Similar articles
-
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.Am J Gastroenterol. 2010 Oct;105(10):2218-27. doi: 10.1038/ajg.2010.218. Epub 2010 Jun 1. Am J Gastroenterol. 2010. PMID: 20517305 Free PMC article. Clinical Trial.
-
Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.Am J Gastroenterol. 2009 Feb;104(2):437-43. doi: 10.1038/ajg.2008.118. Epub 2009 Jan 20. Am J Gastroenterol. 2009. PMID: 19174792 Clinical Trial.
-
Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases.BioDrugs. 2007;21(1):61-3. doi: 10.2165/00063030-200721010-00007. BioDrugs. 2007. PMID: 17263590 Review.
-
VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases.Drugs. 2006;66(10):1371-87. doi: 10.2165/00003495-200666100-00006. Drugs. 2006. PMID: 16903771 Review.
-
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.Gastroenterology. 2000 Aug;119(2):305-9. doi: 10.1053/gast.2000.9370. Gastroenterology. 2000. PMID: 10930365 Clinical Trial.
Cited by
-
Probiotics for inflammatory bowel disease: Is there sufficient evidence?Open Life Sci. 2024 Apr 5;19(1):20220821. doi: 10.1515/biol-2022-0821. eCollection 2024. Open Life Sci. 2024. PMID: 38585636 Free PMC article. Review.
-
Effects of Probiotics in Adults with Gastroenteritis: A Systematic Review and Meta-Analysis of Clinical Trials.Diseases. 2023 Oct 11;11(4):138. doi: 10.3390/diseases11040138. Diseases. 2023. PMID: 37873782 Free PMC article. Review.
-
Strain-specific alterations in gut microbiome and host immune responses elicited by tolerogenic Bifidobacterium pseudolongum.Sci Rep. 2023 Jan 19;13(1):1023. doi: 10.1038/s41598-023-27706-0. Sci Rep. 2023. PMID: 36658194 Free PMC article.
-
Diversity of the gut, vaginal and oral microbiome among pregnant women in South Africa with and without pre-eclampsia.Front Glob Womens Health. 2022 Sep 16;3:810673. doi: 10.3389/fgwh.2022.810673. eCollection 2022. Front Glob Womens Health. 2022. PMID: 36188424 Free PMC article.
-
Plasma Microbiome in COVID-19 Subjects: An Indicator of Gut Barrier Defects and Dysbiosis.Int J Mol Sci. 2022 Aug 15;23(16):9141. doi: 10.3390/ijms23169141. Int J Mol Sci. 2022. PMID: 36012406 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical